CL2009000018A1 - Analogo de la insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. - Google Patents
Analogo de la insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera.Info
- Publication number
- CL2009000018A1 CL2009000018A1 CL2009000018A CL2009000018A CL2009000018A1 CL 2009000018 A1 CL2009000018 A1 CL 2009000018A1 CL 2009000018 A CL2009000018 A CL 2009000018A CL 2009000018 A CL2009000018 A CL 2009000018A CL 2009000018 A1 CL2009000018 A1 CL 2009000018A1
- Authority
- CL
- Chile
- Prior art keywords
- formulation
- vector
- nucleotide sequence
- encodes
- pharmaceutical product
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
- 239000004026 insulin derivative Substances 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 125000003729 nucleotide group Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 108010066381 preproinsulin Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008003566A DE102008003566A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE200810025007 DE102008025007A1 (de) | 2008-05-24 | 2008-05-24 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009000018A1 true CL2009000018A1 (es) | 2009-06-05 |
Family
ID=40473425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009000018A CL2009000018A1 (es) | 2008-01-09 | 2009-01-07 | Analogo de la insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8633156B2 (enExample) |
| EP (1) | EP2229406B1 (enExample) |
| JP (1) | JP5695909B2 (enExample) |
| KR (1) | KR20100111683A (enExample) |
| CN (1) | CN101970476B (enExample) |
| AR (1) | AR070119A1 (enExample) |
| AU (1) | AU2009203810B2 (enExample) |
| BR (1) | BRPI0907119A2 (enExample) |
| CA (1) | CA2711752A1 (enExample) |
| CL (1) | CL2009000018A1 (enExample) |
| CO (1) | CO6290770A2 (enExample) |
| IL (1) | IL206843A0 (enExample) |
| MA (1) | MA31997B1 (enExample) |
| NZ (1) | NZ586589A (enExample) |
| PA (1) | PA8811501A1 (enExample) |
| PE (1) | PE20091305A1 (enExample) |
| TW (1) | TWI433681B (enExample) |
| UY (1) | UY31597A1 (enExample) |
| WO (1) | WO2009087082A2 (enExample) |
| ZA (1) | ZA201003927B (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10017557B2 (en) | 2015-08-28 | 2018-07-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs and use thereof |
| US10159715B2 (en) | 2014-05-29 | 2018-12-25 | Hanmi Pharm. Co., Ltd | Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate |
| US10188703B2 (en) | 2014-05-30 | 2019-01-29 | Hanmi Pharm. Co., Ltd. | Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist |
| US10253082B2 (en) | 2014-01-20 | 2019-04-09 | Hanmi Pharm. Co., Ltd | Long-acting insulin and use thereof |
| US11396534B2 (en) | 2016-09-23 | 2022-07-26 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005046113A1 (de) * | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| US8680049B2 (en) | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
| ES2439499T3 (es) | 2008-12-15 | 2014-01-23 | Zealand Pharma A/S | Análogos de glucagón |
| KR20150116912A (ko) | 2008-12-15 | 2015-10-16 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| JP5635530B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| PT2454282E (pt) | 2009-07-13 | 2015-06-23 | Zealand Pharma As | Análogos de glucagão acilados |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| MA34383B1 (fr) | 2010-06-24 | 2013-07-03 | Zealand Pharma As | Analogues de glucagon |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX2013008005A (es) | 2011-01-20 | 2013-08-21 | Zealand Pharma As | Combinacion de analogos de glucagon acilados con analogos de insulina. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| AR090937A1 (es) | 2012-05-03 | 2014-12-17 | Zealand Pharma As | Compuestos agonista duales de gip-glp-1 y metodos para usarlos |
| BR112015001451B1 (pt) | 2012-07-23 | 2022-03-29 | Zealand Pharma A/S | Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| MX368436B (es) | 2013-10-17 | 2019-10-03 | Zealand Pharma As | Analogos de glucagon acilados. |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| CA2929459C (en) | 2013-11-06 | 2022-05-03 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| ES2883345T3 (es) | 2014-10-29 | 2021-12-07 | Zealand Pharma As | Compuestos agonistas del GIP y métodos |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| CN110615836B (zh) * | 2018-06-20 | 2022-09-13 | 鲁南制药集团股份有限公司 | 一种利拉鲁肽的固相合成方法 |
| CN115702880B (zh) * | 2021-08-12 | 2023-11-03 | 山东新时代药业有限公司 | 一种重组甘精胰岛素注射液及其制备工艺 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
| CA1339416C (en) | 1987-02-25 | 1997-09-02 | Liselotte Langkjaer | Insulin derivatives |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US5225323A (en) * | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
| DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| GR1005153B (el) | 1989-08-29 | 2006-03-13 | The General Hospital Corporation | Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους. |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
| AU5724996A (en) | 1995-05-05 | 1996-11-21 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| TR200001050T2 (tr) | 1997-10-24 | 2000-08-21 | Eli Lilly And Company | Çözünmez insülin bileşimleri |
| US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| CA2322666A1 (en) | 1998-03-12 | 1999-09-16 | Biopore, Inc. | Enhancement of the pro-fertility action of a molecule involved in sperm-egg binding |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| DE19947456A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
| DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
| JP4855640B2 (ja) * | 2001-04-02 | 2012-01-18 | ノヴォ ノルディスク アー／エス | インシュリン前駆体及びその調製方法 |
| EP1545460A4 (en) * | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| ES2327328T3 (es) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
| RU2376314C2 (ru) * | 2002-10-02 | 2009-12-20 | Зилэнд Фарма А/С | Стабилизированные соединения эксендина-4 |
| CN1780854A (zh) * | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
| CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| MX2007000728A (es) * | 2004-07-21 | 2007-03-15 | Ambrx Inc | Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados. |
| US20080280814A1 (en) | 2004-09-17 | 2008-11-13 | Novo Nordisk A/S | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide |
| DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
| ES2370657T3 (es) | 2005-09-14 | 2011-12-21 | Sanofi-Aventis Deutschland Gmbh | Escisión de precursores de insulinas mediante una variante de tripsina. |
| WO2007081824A2 (en) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| US9445113B2 (en) | 2006-01-10 | 2016-09-13 | Thomson Licensing | Methods and apparatus for parallel implementations of 4:4:4 coding |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
-
2009
- 2009-01-06 CN CN200980101942.6A patent/CN101970476B/zh not_active Expired - Fee Related
- 2009-01-06 NZ NZ586589A patent/NZ586589A/en not_active IP Right Cessation
- 2009-01-06 AU AU2009203810A patent/AU2009203810B2/en not_active Ceased
- 2009-01-06 KR KR1020107014964A patent/KR20100111683A/ko not_active Ceased
- 2009-01-06 BR BRPI0907119-9A patent/BRPI0907119A2/pt not_active Application Discontinuation
- 2009-01-06 CA CA2711752A patent/CA2711752A1/en not_active Abandoned
- 2009-01-06 JP JP2010541744A patent/JP5695909B2/ja not_active Expired - Fee Related
- 2009-01-06 WO PCT/EP2009/000018 patent/WO2009087082A2/de not_active Ceased
- 2009-01-06 EP EP09700949.2A patent/EP2229406B1/de active Active
- 2009-01-07 PA PA20098811501A patent/PA8811501A1/es unknown
- 2009-01-07 AR ARP090100036A patent/AR070119A1/es unknown
- 2009-01-07 CL CL2009000018A patent/CL2009000018A1/es unknown
- 2009-01-07 TW TW098100283A patent/TWI433681B/zh not_active IP Right Cessation
- 2009-01-07 UY UY031597A patent/UY31597A1/es not_active Application Discontinuation
- 2009-01-07 PE PE2009000010A patent/PE20091305A1/es not_active Application Discontinuation
-
2010
- 2010-06-02 ZA ZA2010/03927A patent/ZA201003927B/en unknown
- 2010-06-22 US US12/820,727 patent/US8633156B2/en not_active Expired - Fee Related
- 2010-06-25 CO CO10076884A patent/CO6290770A2/es not_active Application Discontinuation
- 2010-07-05 MA MA32984A patent/MA31997B1/fr unknown
- 2010-07-06 IL IL206843A patent/IL206843A0/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10253082B2 (en) | 2014-01-20 | 2019-04-09 | Hanmi Pharm. Co., Ltd | Long-acting insulin and use thereof |
| US10159715B2 (en) | 2014-05-29 | 2018-12-25 | Hanmi Pharm. Co., Ltd | Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate |
| US10188703B2 (en) | 2014-05-30 | 2019-01-29 | Hanmi Pharm. Co., Ltd. | Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist |
| US10017557B2 (en) | 2015-08-28 | 2018-07-10 | Hanmi Pharm. Co., Ltd. | Insulin analogs and use thereof |
| US11396534B2 (en) | 2016-09-23 | 2022-07-26 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CO6290770A2 (es) | 2011-06-20 |
| AU2009203810B2 (en) | 2013-07-25 |
| WO2009087082A2 (de) | 2009-07-16 |
| CN101970476B (zh) | 2014-08-27 |
| WO2009087082A3 (de) | 2009-09-24 |
| EP2229406B1 (de) | 2015-04-22 |
| TW200942257A (en) | 2009-10-16 |
| US8633156B2 (en) | 2014-01-21 |
| EP2229406A2 (de) | 2010-09-22 |
| IL206843A0 (en) | 2010-12-30 |
| BRPI0907119A2 (pt) | 2015-07-14 |
| ZA201003927B (en) | 2011-04-28 |
| JP5695909B2 (ja) | 2015-04-08 |
| AU2009203810A1 (en) | 2009-07-16 |
| NZ586589A (en) | 2012-04-27 |
| TWI433681B (zh) | 2014-04-11 |
| CA2711752A1 (en) | 2009-07-16 |
| JP2011509269A (ja) | 2011-03-24 |
| HK1148542A1 (en) | 2011-09-09 |
| CN101970476A (zh) | 2011-02-09 |
| MA31997B1 (fr) | 2011-01-03 |
| UY31597A1 (es) | 2009-08-31 |
| AR070119A1 (es) | 2010-03-17 |
| KR20100111683A (ko) | 2010-10-15 |
| PE20091305A1 (es) | 2009-09-26 |
| US20110173722A1 (en) | 2011-07-14 |
| PA8811501A1 (es) | 2009-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000018A1 (es) | Analogo de la insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. | |
| CL2009000017A1 (es) | Analogo de insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. | |
| CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
| CL2012003197A1 (es) | Formulación farmacéutica acuosa que comprende 200-1000 u/ml de insulina glargina, con condición de que la concentración de dicha formulación no sea 684 u/ml de insulina glargina; y su uso para tratar diabetes mellitus de tipo i y tipo ii en un paciente. | |
| CL2013000266A1 (es) | Compuestos derivados de cis-tetrahidroespiro(ciclohexan-1,1'-pirido[3,4-b]indol)-4-amina; combinacion y formulacion farmaceutica; y uso en el tratamiento del dolor neuropatico y/o cronico. | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2012003293A1 (es) | Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson. | |
| WO2009089011A3 (en) | Resveratrol formulations | |
| MX352823B (es) | Formulaciones de proteinas que contienen aminoacidos. | |
| CL2007003726A1 (es) | Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer. | |
| WO2009126292A3 (en) | Biologically active peptidomimetic macrocycles | |
| BR112014018575A2 (pt) | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) | |
| WO2008063842A3 (en) | Methods of treating neuropathic pain with agonists of ppar-gamma | |
| CL2012000469A1 (es) | Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit. | |
| CL2013001104A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras. | |
| MX2019015396A (es) | El uso de amisulpride como un anti-emetico. | |
| CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| BR112012033666A2 (pt) | formulações para alimentação por tubo e métodos de uso das mesmas | |
| CL2008003546A1 (es) | Compuestos derivados de piridina; procedimiento de preparacion; composicion farmaceutica de dichos compuestos; y uso en el tratamiento y/o profilaxis de la diabetes mellitus tipo i y/o tipo ii. | |
| EP4613284A3 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| CO6640324A2 (es) | Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa | |
| CL2013001137A1 (es) | Froma cristalina de 1,5 hidrato de sal tartrato de 1-((2s)-2-amino-4 [2,4-bis (trifluorometil)-5,8-dihidro-pirido (3,4-d) pirimidin-7 (6h)-il)-4-oxobutil)-5-5-difluoropiperidin-2-ona; proceso de preparacion; composicion farmaceutica que la comprende; y sus uso para el tratamiento o la prevencion de diabetes u obesidad | |
| WO2010127787A3 (de) | Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften | |
| PA8806501A1 (es) | Triazolotriazinas y triazolopirazinas y su uso |